By Juan Guerra, Donald A. Withers, and Linda M. Boxer In hematopoietic cell development, the c-myb transcription factor plays an important role. c-myb mRNA is expressed at high levels in immature proliferating cells and in leukemic cells. We have investigated the regulatory role of Myb protein binding to the human c-myb promoter. Three Myb binding sites have been described at approximately 600 bp upstream of the cap site. By transient transfection assays in hematopoietic cell lines, we found that deletion of the previously defined most 5' Myb binding site had no effect on activity, whereas deletion of the region containing the remaining two Myb binding sites resulted in an increase in activity in both a T-cell line and a myeloid cell line. To specifically test the importance of these two Myb binding sites, the activity of three-point mutation constructs was mea-HE c-myb PROTO-ONCOGENE is the cellular homologue of the avian myeloblastosis virus (AMV) and avian leukemia virus (E26) transforming genes.'.' The c-Myb protein is a transcription factor important for cell growth; therefore, the regulation of its expression is critically important. c-Myb is a progression factor required for entry into the S phase of the cell ~y c l e .~-~ It has been shown that cmyb mRNA is expressed at higher levels in hematopoietic cells of more immature phenotype and some leukemic cell lines as compared with mature cells?"' Reduction of c-myb expression results in a block to hematopoietic precursor cell proliferation," and homozygous c-myb mutant mice show greatly impaired fetal hepatic hematopoiesis." The importance of the c-myb gene product in leukemic cell proliferation is shown by the inhibition of cellular proliferation by cmyb antisense oligonucleotide^.^ Further, leukemic cells are shown to be more sensitive to this inhibitory effect than normal hematopoietic cells. I3 Myb is a sequence-specific DNA binding protein with the ability to transactivate promoters with the specific consensus sequence PyAACG/TG.'43'5 The c-myb gene product is a highly conserved 75 to 83 kD phosphoprotein that is predominantly expressed in hematopoietic tissues and localized to the nucleus. '6-20 The N-terminal region of the c-Myb protein contains three highly conserved imperfect repeats of 51-52 amino acids that impart c-Myb's DNA binding specificity.'7-21*22 c-Myb has been shown to transactivate several promoters, among these are the chicken miml gene,I5 c-myc promoter,23 human ~-m y b ,~~ H~p 7 0 ,~~ CD4,26 CD34,27 T-cell receptor 6;' and c d~2 .~~ The A-myb and B-myb genes were isolated by cross-hybridization with a c-myb DNA probe. Both A-myb and Bmyb have extensive sequence homology to c-myb, particularly in the DNA binding domain. 30 The three members of the myb gene family show different cell type specificity in their expression. The sequence specificity for DNA binding for c-Myb and B-Myb are ~imilar.~' B-Myb has been shown to function as both a positive and negative regulator of transcription from promoters with Myb binding An imp0-t mechanism for regulation of mouse c-myb expression is a block to transcription elongation within the first intron of the c-myb locus, recognized as a pause site. [34] [35] [36] sured. Mutation of either Myb binding site resulted in an increase in activity compared with the wild-type promoter in T cells. Mutation of both sites produced even higher activity.
Transfection of the Myb site mutants into the myeloid cell line resulted in no change in activity compared with the wild type construct. Results from gel shift analysis, UV crosslinking, and Western blots showed that both c-Myb and BMyb bound to the Myb I and I1 sites. We conclude that the Myb family proteins negatively regulate c-myb expression in T-cell lines in contrast to the positive regulation via these sites, which has been shown in fibroblasts. In addition, in a myeloid cell line, the Myb binding sites are nonfunctional. 0 1995 by The American Society of Hematology.
A correlation between protein binding to the intron 1 pause site and c-myb mRNA levels has been shown using DNA mobility-shift assays. 37 Regulation 
MATERIALS AND METHODS
Cell lines. K.562, Molt-4, and Jurkat cell lines were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum, 2 mmol/L L-glutamine, 50 U/mL penicillin G, and 50 pg/mL streptomycin.
Construction of reporter plasmids. The HindIII-BamH1 fragment of the luciferase reporter vector was derived from pSV232AL-AA5' (obtained from D. Helinski, University of California San Diego). The fragment was cloned into pUC18 and subsequently recut as a HindIII-Kpn I fragment and ligated into the multiple cloning site of Bluescript I1 KS+. The 2.3-kb EcoRI-EcoRI S' flanking region of human c-myb (a kind gift from R. Dalla-Favera, Columbia University, New York, NY) was ligated into the EcoRI site S' of the luciferase gene in Bluescript. To remove a confounding ATG site, the HindIII-Nco I fragment was removed, HindIII linkers were added, and the plasmid religated. A deletion of the 5' flanking region was made using a unique BarnHI restriction site located at -910 from the ATG codon. Further deletions were made using Ba131 endonuclease. Deletions were made at 30-second intervals from BamHl linearized plasmid. The deleted end was then treated with Klenow polymerase, cut with HindIII, and separated by gel electrophoresis. A vector was prepared by removing the HindIIIINor I (Nor I site treated with Klenow polymerase) fragment of the luciferase/ bluescript construct, and the fragment and luciferase vector were ligated. Linear vectors lacking any Bluescript sequences were prepared by restriction enzyme digestion followed by gel purification.
Mutagenesis of Myb I and Myb I1 binding sites was achieved using a technique previously described by Hig~chi.~' The resulting fragment was digested and ligated into the BamH1-Hind111 construct, which had been deleted for the corresponding wild-type fragment. Mutants were screened by restriction enzyme analysis and subsequently sequenced using the Fmol sequencing kit (Promega, Madison, WI) or the Sequenase kit (US Biochemical, Cleveland, OH). Compressions were resolved with deoxyinosine triphosphate or deaza deoxyguanosine triphosphate. The oligonucleotide sequences used for polymerase chain reaction (PCR) primers are (mutated bases are in bold face): Myb I mutant: TAAATTAGAGGTGAAGTT-TATITAAG; Myb I1 mutant: GTCACTAACTAGAGGAAT-TAGAG.
Electrophoretic mobility shift assays (EMSA). Double-stranded oligonucleotide probes of the Myb binding sites were made on an Applied Biosystems (Foster City, CA) 380B oligonucleotide synthesizer. The oligonucleotide sequences used were as follows (Myb binding site underlined): MI: ATTAGAGATGTTA'ITTA'MT; MII:
GTCCT.
The oligonucleotides were synthesized with 5' overhangs and endlabeled with w3*P-deoxycytidine triphosphate and Klenow. Binding conditions were as follows: 10 mmol/L HEPES pH 7.9, 5 mmol/L TRIS-HCI pH 7.5, 50 mmol/L NaC1, I mmol/L EDTA, 1 mmol/L DTT, 10% glycerol, 2 pg poly(d1-dC), 0.5 ng lo4 cpm end-labeled CACTAACAAGTTAAATTAGA; MIII: CACTTGTATTGAAGC-DNA oligonucleotide probe and 5 to 15 pg protein from crude nuclear extract. The binding reaction was conducted at room temperature for 15 minutes and then loaded onto a 5% polyacrylamide gel in glycine buffer (190 mmol/L glycine, 25 mmol/L TRIS-HCI pH 8.5, 1 mmol/L EDTA). The samples were electrophoresed at 30 mA at 4°C. For the competition studies 100-fold molar excess of unlabeled competitor oligonucleotide was added to the binding reaction.
Transfections and luciferase assays. Transfections were performed on cells in log phase. Cells were washed and resuspended in unsupplemented RPMI medium to a final concentration of 3 X IO' cells/mL for Molt-4 cells and 8 X 10' cells/mL for K562 cells and incubated for I O minutes at room temperature and 4"C, respectively. Electroporations were performed with the Bio-Rad Gene Pulser (BioRad Laboratories, Richmond, CA) at 290 mV, 960 pF for Molt-4 cells and 300 mV, 500 pF for K562 cells. The cells were then incubated again for IO minutes at room temperature and 4"C, respectively. Transfected cells were cultured in I O mL of supplemented RPMI for 48 hours.
Cell lysis and luciferase assays were conducted according to the protocol and with reagents supplied with Promega's Luciferase Assay System. Luciferase measurements were performed on an LKB 125 1 luminometer (Wallac Inc, Gaithersburg, MD). A plasmid to control for variation in transfection efficiency could not be used because the c-myb promoter was found to compete with the other commonly used promoters. Equal amounts of extract protein were assayed, and each transfection was repeated at least six times with at least three different DNA preparations. The average value with the SD is plotted.
Ultraviolet cross-linking and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). EMSA was performed as described above except that the reaction was scaled up three-fold. The wet gel was exposed to film to locate the complexes. UV crosslinking was performed essentially as describedM on a short-wave UV light box at 4°C for 1 hour. The region of the gel containing the complexes was cut out, and the complexes were eluted at room temperature overnight in 50 mmom TRIS HCI pH 7.9, 0.1% SDS, 0.1 mmol/L EDTA, 5 mmol/L DTT, 150 mmom NaCI, 0.1 mg/mL bovine serum albumin (BSA). The eluted protein was precipitated with 4 volumes of acetone, washed with ethanol, and air dried. After resuspension in Laemmli loading buffer, SDS-PAGE was performed, and the proteins were visualized by autoradiography. Western blots were performed as above with either UV cross-linked or noncrosslinked protein. The anti-Myb antibody (BP2) was obtained from J. Lipsick, Stanford; it was used at a dilution of 1:10,000. This antibody recognizes the DNA binding domain of c-Myb from man, mouse, and chicken, and it cross-reacts weakly with B-Myb.
RESULTS
The region of the c-myb promoter containing the Myb binding sites functions as a negative regulator of expression. To elucidate the role of the 5' flanking region of c-myb, we constructed various deletions of the promoter using unique restriction sites and Ba131 exonuclease (Fig 1A) . These deletions of the c-myb promoter region were linked to a luciferase reporter gene in a bluescript vector. The constructs were electroporated into either the myeloid cell line K562 or the T-cell line Molt-4. To address the potentially confounding effect of putative Myb binding sites in the bluescript vector,45 we performed control experiments using linear fragments from which the vector sequences had been removed. Using three such constructs, we found little change in activity compared with the corresponding supercoiled myb promoter-luciferase bluescript constructs in M o l t 4 a n d K562 cells. (Fig 2) .
Finally we assayed the activity of a construct that deleted the remaining two Myb binding sites (Del). This construct included 73 1 bases upstream from the ATG codon. Luciferase activity for this construct was higher in both cell lines than either of the two previous constructs. In Molt-4 the relative luciferase activity was 12.81 and in K562 it was 4.21 (Fig 2) . This represents a 2.2-fold and a 4.3-fold change in activity, respectively, over the construct containing the intact Myb sites.
From these findings we conclude that the 5' most Myb binding site (Myb 111) is not active in human T-and myeloid cell lines. However, the increase in activity of the Myb I1 and Myb I deletion indicates that the region containing these two sites is an important negative regulatory region of cmyb gene expression in these hematopoietic cell lines. Myb binding sites Myh I and Myh I1 are responsible for cis-acting negative regulation in T cells. To determine whether the Myb I and Myb I1 binding sites were the cisacting elements responsible for the change in activity with the deletion constructs, we used three Myb binding site mutants (see Fig IB) . These mutants replace four of the six bases in the Myb binding sites to effectively destroy the sites. The mutations were introduced into the -910 construct (MI-MIII). Myb I and Myb I1 were mutated individually and together. We did not mutate Myb Ill because our previous results indicated that it contributed little to the regulation of expression of c-myh.
The relative luciferase activity of the Myb I1 mutant was 1.32-fold higher than the wild type construct in Molt 4 cells (7.52 v 5.70), while the activity of the Myb I mutant was 1.85-fold higher (10.53 v 5.70). However, when we transfected Molt-4 cells with the MI and MI1 double mutant, the relative luciferase activity increased to 19.81, a 3.5-fold change (Fig 3) . The increase in activity seen with the double mutant is higher than that seen when both sites are deleted, indicating that the deleted region may also include a positive regulatory element. Our findings suggest that the Myb I site is more active than the Myb I1 site; furthermore, the increase in activity seen with the double mutant indicates that the interaction between Myb I and Myb I1 is additive in Molt- In K562 cells the relative luciferase activity of the Myb I1 mutant was 0.88 that of the wild type construct and the relative activity of the Myb I mutant was 1.37 that of the wild type construct. The activity obtained with the double mutant MI&II was 1.18 relative to the wild type promoter construct (Fig 3) . These numbers are not significantly different from the activity of the wild type promoter; these results suggest that the Myb binding sites are not functional in K562 cells.
EMSA shows three complexes. EMSAs were performed with both Molt-4 and K562 nuclear extracts; the results were identical with both cell lines. We used double stranded oligonucleotides of the Myb binding sites and of the two mutated Myb sites. We found that the Myb I and Myb I1 sites yielded similar patterns with an intense faster migrating complex (3 in Fig 4A) and two slower migrating complexes ( 1 and 2 in Fig 4A) . A greater amount of the slowest migrating complex ( 1 in Fig 4A) was formed with the Myb I site, while the Myb I1 site yielded more of the intermediate complex (2 in Fig 4A) and no complex 1. Three bands of high electrophoretic mobility were also seen. The middle complex was nonspecific (labeled NS in Fig 4) ; the other two complexes were specific and varied in amount in different nuclear extract preparations. They may represent proteolytic breakdown products of proteins in the slower migrating complexes. We have not further characterized them. The Myb Ill oligonucleotide did not form any of the complexes 1-3 seen with the Myb I and Myb I1 oligonucleotides (Fig 4A) . The two mutated Myb sites, MI Mut and MI1 Mut, did not form complexes 1 through 3 seen with the wild-type Myb sequences (Fig 4A) .
Competition studies showed that a 100-fold molar excess of Myb I competed against labeled Myb I and complexes 2 and 3 formed with labeled Myb I1 (Fig 4B and C) . A 100-fold molar excess of Myb I1 competed against labeled Myb I1 and complexes 2 and 3 formed with labeled Myb I (Fig  4B and C) . Competition with either Myb Ill or an irrelevant sequence (NF-KB site) at 100-fold molar excess had no effect on the complexes. The mutated Myb I site (MI Mut) did not compete against the complexes formed with labeled Myb I (Fig 4B) and, likewise, the mutated Myb I1 site (MI1 Mut) did not compete against the complexes formed with labeled Myb I1 (Fig 4C) . We conclude that the Myb I and I1 sites form specific complexes and cross-compete with each other; however, the Myb I11 site and the mutated Myb I and Myb I1 sites do not form these complexes or compete against them. Complexes similar to those observed with Molt-4 nuclear extract are formed with labeled Myb I and I1 oligonucleotides with nuclear extract from K562 cells. Nuclear extract from K562 cells yielded complexes 1 through 3 with labeled Myb I and complexes 2 and 3 with labeled Myb I1 (Fig 4D) . These complexes were indistinguishable from those formed with Molt-4 nuclear extract (Fig 4A) .
Both c-and B-Myh hind to the Myh binding sites in the c-myh 5'Jlank. Because c-and B-Myb have been reported to bind to identical DNA sequences, we wanted to determine which protein was present in the bands observed in EMSA. Northern analysis showed that the Molt-4 cell line expressed high levels of c-myh RNA and that B-myh mRNA was also present. In K562 cells the amount of c-myh mRNA was lower than that of B-myh, while the amount of B-myh mRNA was approximately equivalent in Molt-4 and K562 cells (unpublished data). Western analysis of nuclear extracts from these two cell lines confirmed these results at the protein level (J.G. and L.M.B., unpublished data, April 1994). The
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anti-Myb antibody we used for the Western blot is capable of recognizing chicken, mouse, and human c-Myb, and it cross-reacted weakly with B-myb.
The EMSA complexes from Myb I and Myb I1 were exposed to UV light to cross-link the labeled DNA to the proteins and then eluted from the gel. SDS-PAGE showed that each complex contained two proteins (Fig 5A) . When the migration was corrected for the bound oligonucleotide, the molecular masses of these proteins were 75 and 108 kD. These correspond 
DISCUSSION
The central role that c-Myb plays in the regulation of hematopoietic cell development has fueled research into the regulation of its expression. We chose to examine c-myb regulation in hematopoietic cells because c-myb is primarily expressed in these cells. The regulation of c-myb expression is complex, and both transcription initiation and a block to transcription elongation have been shown to be important. We have focused on transcription initiation of c-myb in this study. Our preliminary data show that the activity of the c- We used UV cross-linking of each of the EMSA complexes to determine whether any proteins other than c-Myb contacted these sequences. Our results show that proteins of the same sizes as c-and B-Myb are present in each complex with more B-Myb in the complexes of lower mobility, I and 2. We have confirmed by Western analysis that the Myb proteins are present in the EMSA complexes. We have shown that c-and B-Myb contact DNA in each of the cornplexes C1-C3, but the presence of accessory proteins in the complexes may cause the different migration patterns of the C l and C2 complexes on EMSA.
Whether both c-Myb and B-Myb have access to these sites in vivo and thus function as negative regulators of cmyb expression in T cells is unclear. Although both c-and B-Myb in K562 nuclear extract bind to these sites in vitro, there is no functional activity associated with these sites in K562 cells. It is unclear whether access of the proteins to these sites is limited in K562 cells or whether accessory proteins that are required for interactions with other proteins of the transcriptional apparatus are lacking in K562 cells.
In transient transfection experiments in fibroblasts c-Myb has been shown to positively autoregulate its own expression*'; the effect of B-Myb was not determined. In the Molt-4 T cell line, we attempted to determine whether cotransfection with a c-myb expression vector resulted in downregulation of the c-myb promoter. However, we saw no change in reporter activity even at ratios of 5: 1 of the c-myb expression vector to c-myb promoter construct. We believe that our inability to alter expression of the c-myb reporter construct is due to the high endogenous level of c-Myb expression in these cells. In support of this, we saw by Western analysis that For personal use only. on October 3, 2017. by guest www.bloodjournal.org From have been unable to clearly document protection of the Myb sites in Molt4 cells by in vivo footprinting. Although these negative results have other interpretations, it is possible that the majority of the Myb sites are not occupied in cells that express high levels of c-Myb. Our preliminary data suggest that the Myb I and Myb I1 sites are occupied in resting primary human T cells that express low levels of c-Myb. In activated T cells that express high levels of c-Myb, we are not able to detect protein binding to these sites. How access to the majority of these sites would be blocked is not clear, but it has been shown recently that c-Myb binding to DNA is sensitive to methylation of cytosine residues.46 Other regions of the c-myb promoter function as positive regulators of expression in hematopoietic cells and we are currently investigating these.
